Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.
Adhoc Press Release
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals
Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
Olav Zilian, MD, PhD, EMBA
Mirabaud Securities Ltd
David Sherman, Ph.D.(AC)
Please use the button below to view and download Analyst reports
|Mar 18, 2021||Kuros will publish its Annual Report for 2020|
|Apr 19, 2021||Kuros will hold its Annual Shareholders' Meeting|
|Aug 11, 2021||Kuros will publish its Half Year Report for H1 2021|